Exact Mass: 436.297729
Exact Mass Matches: 436.297729
Found 500 metabolites which its exact mass value is equals to given mass value 436.297729
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
DHAP(18:0)
C21H41O7P (436.25897660000004)
DHAP(18:0) is the octadecanoyl derivative of Dihydroxyacetone phosphate. It is also known as an alkyl-DHAP. This compound is formed by octadecanoic acid reacting with DHAP. Alkyl-DHAPs are intermediates in the synthesis of ether phospholipids. The initial steps of ether phospholipid biosynthesis take place in peroxisomes. Alkyl-dihydroxyacetonephosphate synthase is the peroxisomal enzyme that actually introduces the ether linkage. Levels of Alkyl-DHAP have been found to be strongly reduced in human fibroblasts derived from Zellweger syndrome and rhizomelic chondrodysplasia punctata patients. Four other enzymes are known to be involved in the metabolism of acyl-DHAP and alkyl-DHAP. These include: acyl-DHAP/alkyl-DHAP oxidoreductase, DHAP acyltransferase, alkyl-DHAP phosphohydrolase, and a dinitrofluorobenzene-insensitive acyl-DHAP acylhydrolase. Dihydroxyacetone phosphate (DHAP) is a biochemical compound primarily involved in the glycolysis metabolic pathway. DHAP is also the product of the dehydrogenation of L-glycerol-3-phosphate which is part of the entry of glycerol (sourced from triglycerides) into the glycolytic pathway. Conversely, reduction of glycolysis-derived DHAP to L-glycerol-3-phosphate provides adipose cells with the activated glycerol backbone they require to synthesize new triglycerides. Both reactions are catalyzed by the enzyme glycerol 3-phosphate dehydrogenase with NAD+/NADH as cofactor. DHAP may be referred to as glycerone phosphate in older texts. 1-Octadecyl-glycerone-3-phosphate is an intermediate in Ether lipid metabolism. DHAP(18:0) or 1-Octadecanoyl-glycerone-3-phosphate is the precursor to 1-Octadecyl-glycerone-3-phosphate DHAP(18:0e) which is generated via alkylglycerone phosphate synthase (EC: 2.5.1.26). Ether lipids are lipids in which one or more of the carbon atoms on glycerol is bonded to an alkyl chain via an ether linkage, as opposed to the usual ester linkage. Ether lipids are called plasmalogens (1-O-1-alkenyl-2-acylglycerophospholipids) if these are glycerol-containing phospholipids with an unsaturated O-(1-alkenyl) (vinyl ether) group at the first position on the glycerol chain. Plasmalogens as well as some 1-O-alkyl lipids are ubiquitous and sometimes major parts of the cell membranes in mammals and anaerobic bacteria. In archaea, ether lipids are the major polar lipids in the cell envelope and their abundance is one of the major characteristics that separate this group of prokaryotes from the bacteria. In these cells, diphytanylglycerolipids or bipolar macrocyclic tetraethers can form covalently linked bilayers. [HMDB] DHAP(18:0) is the octadecanoyl derivative of dihydroxyacetone phosphate. It is also known as an alkyl-DHAP. This compound is formed by octadecanoic acid reacting with DHAP. Alkyl-DHAPs are intermediates in the synthesis of ether phospholipids. The initial steps of ether phospholipid biosynthesis take place in peroxisomes. Alkyl-dihydroxyacetonephosphate synthase is the peroxisomal enzyme that actually introduces the ether linkage. Levels of Alkyl-DHAP have been found to be strongly reduced in human fibroblasts derived from Zellweger syndrome and rhizomelic chondrodysplasia punctata patients. Four other enzymes are known to be involved in the metabolism of acyl-DHAP and alkyl-DHAP. These include: acyl-DHAP/alkyl-DHAP oxidoreductase, DHAP acyltransferase, alkyl-DHAP phosphohydrolase, and a dinitrofluorobenzene-insensitive acyl-DHAP acylhydrolase. Dihydroxyacetone phosphate (DHAP) is a biochemical compound primarily involved in the glycolysis metabolic pathway. DHAP is also the product of the dehydrogenation of L-glycerol-3-phosphate which is part of the entry of glycerol (sourced from triglycerides) into the glycolytic pathway. Conversely, reduction of glycolysis-derived DHAP to L-glycerol-3-phosphate provides adipose cells with the activated glycerol backbone they require to synthesize new triglycerides. Both reactions are catalyzed by the enzyme glycerol 3-phosphate dehydrogenase with NAD+/NADH as cofactor. DHAP may be referred to as glycerone phosphate in older texts. 1-Octadecyl-glycerone-3-phosphate is an intermediate in Ether lipid metabolism. DHAP(18:0) or 1-Octadecanoyl-glycerone-3-phosphate is the precursor to 1-Octadecyl-glycerone-3-phosphate DHAP(18:0e) which is generated via alkylglycerone phosphate synthase (EC: 2.5.1.26). Ether lipids are lipids in which one or more of the carbon atoms on glycerol is bonded to an alkyl chain via an ether linkage, as opposed to the usual ester linkage. Ether lipids are called plasmalogens (1-O-1-alkenyl-2-acylglycerophospholipids) if these are glycerol-containing phospholipids with an unsaturated O-(1-alkenyl) (vinyl ether) group at the first position on the glycerol chain. Plasmalogens as well as some 1-O-alkyl lipids are ubiquitous and sometimes major parts of the cell membranes in mammals and anaerobic bacteria. In archaea, ether lipids are the major polar lipids in the cell envelope and their abundance is one of the major characteristics that separate this group of prokaryotes from the bacteria. In these cells, diphytanylglycerolipids or bipolar macrocyclic tetraethers can form covalently linked bilayers. (Wikipedia)
Demethylphylloquinone
Demethylphylloquinone is a form of vitamin K that occurs in nature as part of a series of compounds with a common 2-methyl-1,4 naphthoquinone nucleus and differing isoprenoid side chains at the 3 position. Vitamin K forms comprise a single major plant form, phylloquinone with a phytyl side chain and a family of bacterially synthesized menaquinones (MKs) with multiprenyl side chains. Bacterially produced menaquinones are biologically active forms of vitamin K that are present in high concentrations in the human lower bowel. Both phylloquinone and menaquinones are bioactive in hepatic gamma-carboxylation but long-chain MKs are less well absorbed. Liver stores of vitamin K are relatively small. The hepatic reserves of phylloquinone (approximately 10\\% of the total) are labile and turn over at a faster rate than menaquinones. Vitamin K is recognised as a factor required for normal blood coagulation, and in relation to its role in bone metabolism. Vitamin K is a substrate for a liver microsomal enzyme that catalyzes the conversion of specific glutamyl residues to gamma-carboxyglutamyl residues in a limited number of proteins. These include the vitamin K-dependent clotting factors: prothrombin (factor II), factor VII, factor IX, and factor X. In the absence of vitamin K, nonfunctional clotting factors are synthesized and hemorrhage can result. Vitamin K is a coenzyme for glutamate carboxylase, which mediates the conversion of glutamate to gamma-carboxyglutamate (Gla). There are at least three Gla proteins associated with bone tissue, of which osteocalcin is the most abundant and best known. Trabecular and cortical bone appear to contain substantial concentrations of both phylloquinone and menaquinones. (PMID: 8642453, 8527227, 15018483, 1573141) [HMDB] Demethylphylloquinone is a form of vitamin K that occurs in nature as part of a series of compounds with a common 2-methyl-1,4 naphthoquinone nucleus and differing isoprenoid side chains at the 3 position. Vitamin K forms comprise a single major plant form, phylloquinone with a phytyl side chain and a family of bacterially synthesized menaquinones (MKs) with multiprenyl side chains. Bacterially produced menaquinones are biologically active forms of vitamin K that are present in high concentrations in the human lower bowel. Both phylloquinone and menaquinones are bioactive in hepatic gamma-carboxylation but long-chain MKs are less well absorbed. Liver stores of vitamin K are relatively small. The hepatic reserves of phylloquinone (approximately 10\\% of the total) are labile and turn over at a faster rate than menaquinones. Vitamin K is recognised as a factor required for normal blood coagulation, and in relation to its role in bone metabolism. Vitamin K is a substrate for a liver microsomal enzyme that catalyzes the conversion of specific glutamyl residues to gamma-carboxyglutamyl residues in a limited number of proteins. These include the vitamin K-dependent clotting factors: prothrombin (factor II), factor VII, factor IX, and factor X. In the absence of vitamin K, nonfunctional clotting factors are synthesized and hemorrhage can result. Vitamin K is a coenzyme for glutamate carboxylase, which mediates the conversion of glutamate to gamma-carboxyglutamate (Gla). There are at least three Gla proteins associated with bone tissue, of which osteocalcin is the most abundant and best known. Trabecular and cortical bone appear to contain substantial concentrations of both phylloquinone and menaquinones. (PMID: 8642453, 8527227, 15018483, 1573141).
simvastatin hydroxy acid
simvastatin hydroxy acid is a metabolite of simvastatin. Simvastatin is a hypolipidemic drug used to control elevated cholesterol, or hypercholesterolemia. It is a member of the statin class of pharmaceuticals. Simvastatin is a synthetic derivate of a fermentation product of Aspergillus terreus. The drug is marketed generically and under the trade name Zocor. (Wikipedia) C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor
LysoPA(18:1(9Z)/0:0)
C21H41O7P (436.25897660000004)
LysoPA(18:1(9Z)/0:0) is a lysophosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. Fatty acids containing 16 and 18 carbons are the most common. Lysophosphatidic acid is the simplest possible glycerophospholipid. It is the biosynthetic precursor of phosphatidic acid. Although it is present at very low levels only in animal tissues, it is extremely important biologically, influencing many biochemical processes. In particular, lysophosphatidic acid is an intercellular lipid mediator with growth factor-like activities, and is rapidly produced and released from activated platelets to influence target cells. 1-Palmitoyl lysophosphatidic acid is the major component of lysophosphatidic acid (LPA) in plasma, and is in a reduced ratio in individuals with gynecological cancers (PMID 11585410). LPA is a pluripotent lipid mediator controlling growth, motility, and differentiation, that has a strong influence on the chemotaxis and ultrastructure of human neutrophils (PMID 7416233). In serum and plasma, LPA is mainly converted from lysophospholipids, whereas in platelets and some cancer cells it is converted from phosphatidic acid. In each pathway, at least two phospholipase activities are required: phospholipase A1 (PLA1)/PLA2 plus lysophospholipase D (lysoPLD) activities are involved in the first pathway and phospholipase D (PLD) plus PLA1/PLA2 activities are involved in the second pathway. (PMID 15271293).
Ganoderal A
Ganoderal A is found in mushrooms. Ganoderal A is a constituent of Ganoderma lucidum (reishi) Constituent of Ganoderma lucidum (reishi). Ganoderal A is found in mushrooms. Ganoderal A, an oxygenated sterol from G. lucidum, is a cholesterol synthesis inhibitor[1]. Ganoderal A, an oxygenated sterol from G. lucidum, is a cholesterol synthesis inhibitor[1].
Pangamic acid
Pangamic acid is found in apricot. Pangamic acid is isolated from apricot kernel, also said to be present in cereals etc. Said to be a vitamin of significance in, inter alia, hypertension control Pangamic acid is also known as vitamin B15, but it is not widely accepted as a vitamin for it has not been shown to be essential in the human diet, and a deficiency in consumption of pangamic acid is not known to be associated with any disease. Pangamic acid is an ester derived from gluconic acid and dimethylglycine. It was first isolated by Ernst T. Krebs from apricot kernels, and has since been identified in some foods such as pulses. Also found in rice bran & apricot kernels Isolated from apricot kernel, also said to be present in cereals etc. Said to be a vitamin of significance in, inter alia, hypertension control
Varanic acid
Varanic acid is a bile acid that will accumulate in patients with deficiencies in the peroxisomal d-bifunctional protein. The final steps in bile acid biosynthesis take place in peroxisomes and involve oxidative cleavage of the side chain of C27-5beta-cholestanoic acids leading to the formation of the primary bile acids cholic acid and chenodeoxycholic acid. The enoyl-CoA hydratase and beta-hydroxy acyl-CoA dehydrogenase reactions involved in the chain shortening of C27-5beta-cholestanoic acids are catalyzed by peroxisomal d-bifunctional protein. (PMID: 9831634) [HMDB] Varanic acid is a bile acid that will accumulate in patients with deficiencies in the peroxisomal d-bifunctional protein. The final steps in bile acid biosynthesis take place in peroxisomes and involve oxidative cleavage of the side chain of C27-5beta-cholestanoic acids leading to the formation of the primary bile acids cholic acid and chenodeoxycholic acid. The enoyl-CoA hydratase and beta-hydroxy acyl-CoA dehydrogenase reactions involved in the chain shortening of C27-5beta-cholestanoic acids are catalyzed by peroxisomal d-bifunctional protein. (PMID: 9831634).
LysoPA(0:0/18:1(9Z))
C21H41O7P (436.25897660000004)
LysoPA(0:0/18:1(9Z)) is a lysophosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. Fatty acids containing 16 and 18 carbons are the most common. Lysophosphatidic acid is the simplest possible glycerophospholipid. It is the biosynthetic precursor of phosphatidic acid. Although it is present at very low levels only in animal tissues, it is extremely important biologically, influencing many biochemical processes. In particular, lysophosphatidic acid is an intercellular lipid mediator with growth factor-like activities, and is rapidly produced and released from activated platelets to influence target cells. 1-Palmitoyl lysophosphatidic acid is the major component of lysophosphatidic acid (LPA) in plasma, and is in a reduced ratio in individuals with gynecological cancers (PMID 11585410). LPA is a pluripotent lipid mediator controlling growth, motility, and differentiation, that has a strong influence on the chemotaxis and ultrastructure of human neutrophils (PMID 7416233). In serum and plasma, LPA is mainly converted from lysophospholipids, whereas in platelets and some cancer cells it is converted from phosphatidic acid. In each pathway, at least two phospholipase activities are required: phospholipase A1 (PLA1)/PLA2 plus lysophospholipase D (lysoPLD) activities are involved in the first pathway and phospholipase D (PLD) plus PLA1/PLA2 activities are involved in the second pathway. (PMID 15271293).
Manglupenone
Manglupenone is found in fruits. Manglupenone is a constituent of the stem bark of Mangifera indica var. Dusehri Constituent of the stem bark of Mangifera indica variety Dusehri. Manglupenone is found in fruits.
(R)-1-O-[b-D-Apiofuranosyl-(1->2)-b-D-glucopyranoside]-1,3-octanediol
(R)-1-O-[b-D-Apiofuranosyl-(1->2)-b-D-glucopyranoside]-1,3-octanediol is found in fruits. (R)-1-O-[b-D-Apiofuranosyl-(1->2)-b-D-glucopyranoside]-1,3-octanediol is a constituent of calabash tree (Crescentia cujete) fruits. Constituent of calabash tree (Crescentia cujete) fruits. (R)-1-O-[b-D-Apiofuranosyl-(1->2)-b-D-glucopyranoside]-1,3-octanediol is found in fruits.
24,24-Dfhv
C27H42F2O2 (436.31526959999997)
N,N-Dihexyl-2-(4-fluorophenyl)indole-3-acetamide
C28H37FN2O (436.28897639999997)
DG(2:0/20:3(5Z,8Z,11Z)-O(14R,15S)/0:0)
DG(2:0/20:3(5Z,8Z,11Z)-O(14R,15S)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:3(5Z,8Z,11Z)-O(14R,15S)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:3(5Z,8Z,11Z)-O(14R,15S)/2:0/0:0)
DG(20:3(5Z,8Z,11Z)-O(14R,15S)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:3(5Z,8Z,11Z)-O(14R,15S)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:3(5Z,8Z,11Z)-O(14R,15S))
DG(2:0/0:0/20:3(5Z,8Z,11Z)-O(14R,15S)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:3(5Z,8Z,11Z)-O(14R,15S)/0:0/2:0)
DG(20:3(5Z,8Z,11Z)-O(14R,15S)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:3(5Z,8Z,14Z)-O(11S,12R)/0:0)
DG(2:0/20:3(5Z,8Z,14Z)-O(11S,12R)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:3(5Z,8Z,14Z)-O(11S,12R)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:3(5Z,8Z,14Z)-O(11S,12R)/2:0/0:0)
DG(20:3(5Z,8Z,14Z)-O(11S,12R)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:3(5Z,8Z,14Z)-O(11S,12R)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:3(5Z,8Z,14Z)-O(11S,12R))
DG(2:0/0:0/20:3(5Z,8Z,14Z)-O(11S,12R)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:3(5Z,8Z,14Z)-O(11S,12R)/0:0/2:0)
DG(20:3(5Z,8Z,14Z)-O(11S,12R)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:3(5Z,11Z,14Z)-O(8,9)/0:0)
DG(2:0/20:3(5Z,11Z,14Z)-O(8,9)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:3(5Z,11Z,14Z)-O(8,9)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:3(5Z,11Z,14Z)-O(8,9)/2:0/0:0)
DG(20:3(5Z,11Z,14Z)-O(8,9)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:3(5Z,11Z,14Z)-O(8,9)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:3(5Z,11Z,14Z)-O(8,9))
DG(2:0/0:0/20:3(5Z,11Z,14Z)-O(8,9)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:3(5Z,11Z,14Z)-O(8,9)/0:0/2:0)
DG(20:3(5Z,11Z,14Z)-O(8,9)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:3(8Z,11Z,14Z)-O(5,6)/0:0)
DG(2:0/20:3(8Z,11Z,14Z)-O(5,6)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:3(8Z,11Z,14Z)-O(5,6)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:3(8Z,11Z,14Z)-O(5,6)/2:0/0:0)
DG(20:3(8Z,11Z,14Z)-O(5,6)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:3(8Z,11Z,14Z)-O(5,6)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:3(8Z,11Z,14Z)-O(5,6))
DG(2:0/0:0/20:3(8Z,11Z,14Z)-O(5,6)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:3(8Z,11Z,14Z)-O(5,6)/0:0/2:0)
DG(20:3(8Z,11Z,14Z)-O(5,6)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(20)/0:0)
DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(20)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(20)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,14Z)-OH(20)/2:0/0:0)
DG(20:4(5Z,8Z,11Z,14Z)-OH(20)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(5Z,8Z,11Z,14Z)-OH(20)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(5Z,8Z,11Z,14Z)-OH(20))
DG(2:0/0:0/20:4(5Z,8Z,11Z,14Z)-OH(20)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,14Z)-OH(20)/0:0/2:0)
DG(20:4(5Z,8Z,11Z,14Z)-OH(20)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:4(6E,8Z,11Z,14Z)-OH(5S)/0:0)
DG(2:0/20:4(6E,8Z,11Z,14Z)-OH(5S)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(6E,8Z,11Z,14Z)-OH(5S)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(6E,8Z,11Z,14Z)-OH(5S)/2:0/0:0)
DG(20:4(6E,8Z,11Z,14Z)-OH(5S)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(6E,8Z,11Z,14Z)-OH(5S)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(6E,8Z,11Z,14Z)-OH(5S))
DG(2:0/0:0/20:4(6E,8Z,11Z,14Z)-OH(5S)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(6E,8Z,11Z,14Z)-OH(5S)/0:0/2:0)
DG(20:4(6E,8Z,11Z,14Z)-OH(5S)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)/0:0)
DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,14Z)-OH(19S)/2:0/0:0)
DG(20:4(5Z,8Z,11Z,14Z)-OH(19S)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(5Z,8Z,11Z,14Z)-OH(19S)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))
DG(2:0/0:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,14Z)-OH(19S)/0:0/2:0)
DG(20:4(5Z,8Z,11Z,14Z)-OH(19S)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)/0:0)
DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,14Z)-OH(18R)/2:0/0:0)
DG(20:4(5Z,8Z,11Z,14Z)-OH(18R)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(5Z,8Z,11Z,14Z)-OH(18R)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))
DG(2:0/0:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,14Z)-OH(18R)/0:0/2:0)
DG(20:4(5Z,8Z,11Z,14Z)-OH(18R)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(17)/0:0)
DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(17)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(17)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,14Z)-OH(17)/2:0/0:0)
DG(20:4(5Z,8Z,11Z,14Z)-OH(17)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(5Z,8Z,11Z,14Z)-OH(17)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(5Z,8Z,11Z,14Z)-OH(17))
DG(2:0/0:0/20:4(5Z,8Z,11Z,14Z)-OH(17)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,14Z)-OH(17)/0:0/2:0)
DG(20:4(5Z,8Z,11Z,14Z)-OH(17)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)/0:0)
DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,14Z)-OH(16R)/2:0/0:0)
DG(20:4(5Z,8Z,11Z,14Z)-OH(16R)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(5Z,8Z,11Z,14Z)-OH(16R)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))
DG(2:0/0:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,14Z)-OH(16R)/0:0/2:0)
DG(20:4(5Z,8Z,11Z,14Z)-OH(16R)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:4(5Z,8Z,11Z,13E)-OH(15S)/0:0)
DG(2:0/20:4(5Z,8Z,11Z,13E)-OH(15S)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(5Z,8Z,11Z,13E)-OH(15S)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,13E)-OH(15S)/2:0/0:0)
DG(20:4(5Z,8Z,11Z,13E)-OH(15S)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(5Z,8Z,11Z,13E)-OH(15S)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(5Z,8Z,11Z,13E)-OH(15S))
DG(2:0/0:0/20:4(5Z,8Z,11Z,13E)-OH(15S)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,13E)-OH(15S)/0:0/2:0)
DG(20:4(5Z,8Z,11Z,13E)-OH(15S)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:4(5Z,8Z,10E,14Z)-OH(12S)/0:0)
DG(2:0/20:4(5Z,8Z,10E,14Z)-OH(12S)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(5Z,8Z,10E,14Z)-OH(12S)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,10E,14Z)-OH(12S)/2:0/0:0)
DG(20:4(5Z,8Z,10E,14Z)-OH(12S)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(5Z,8Z,10E,14Z)-OH(12S)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(5Z,8Z,10E,14Z)-OH(12S))
DG(2:0/0:0/20:4(5Z,8Z,10E,14Z)-OH(12S)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,10E,14Z)-OH(12S)/0:0/2:0)
DG(20:4(5Z,8Z,10E,14Z)-OH(12S)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:4(5E,8Z,12Z,14Z)-OH(11R)/0:0)
DG(2:0/20:4(5E,8Z,12Z,14Z)-OH(11R)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(5E,8Z,12Z,14Z)-OH(11R)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(5E,8Z,12Z,14Z)-OH(11R)/2:0/0:0)
DG(20:4(5E,8Z,12Z,14Z)-OH(11R)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(5E,8Z,12Z,14Z)-OH(11R)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(5E,8Z,12Z,14Z)-OH(11R))
DG(2:0/0:0/20:4(5E,8Z,12Z,14Z)-OH(11R)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(5E,8Z,12Z,14Z)-OH(11R)/0:0/2:0)
DG(20:4(5E,8Z,12Z,14Z)-OH(11R)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:4(5Z,7E,11Z,14Z)-OH(9)/0:0)
DG(2:0/20:4(5Z,7E,11Z,14Z)-OH(9)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(5Z,7E,11Z,14Z)-OH(9)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,7E,11Z,14Z)-OH(9)/2:0/0:0)
DG(20:4(5Z,7E,11Z,14Z)-OH(9)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(5Z,7E,11Z,14Z)-OH(9)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(5Z,7E,11Z,14Z)-OH(9))
DG(2:0/0:0/20:4(5Z,7E,11Z,14Z)-OH(9)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,7E,11Z,14Z)-OH(9)/0:0/2:0)
DG(20:4(5Z,7E,11Z,14Z)-OH(9)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
Lancifodilactone F
Lancifodilactone F is a tetracyclic triterpenoid that is a rearranged pentanortriterpenoid derived from cycloartane. Isolated from the leaves and stem of Schisandra lancifolia, it exhibits anti-HIV activity. It has a role as a metabolite and an anti-HIV agent. It is an oxaspiro compound, a tetracyclic triterpenoid, a gamma-lactone, a diol and a monocarboxylic acid. A tetracyclic triterpenoid that is a rearranged pentanortriterpenoid derived from cycloartane. Isolated from the leaves and stem of Schisandra lancifolia, it exhibits anti-HIV activity.
ganoderal A
Ganoderal A is a triterpenoid. ganoderal A is a natural product found in Ganoderma pfeifferi, Ganoderma, and Ganoderma lucidum with data available. Ganoderal A, an oxygenated sterol from G. lucidum, is a cholesterol synthesis inhibitor[1]. Ganoderal A, an oxygenated sterol from G. lucidum, is a cholesterol synthesis inhibitor[1].
Azadirone
A tetracyclic triterpenoid that is 4,4,8-trimethylandrosta-1,14-diene substituted by an oxo group at position 3, an acetoxy group at position 7 and a furan-3-yl group at position 17. Isolated from Azadirachta indica, it exhibits antiplasmodial and antineoplastic activities.
(ent-2alpha,3beta,13Z)-3-Angeloyloxy-8(17),13-labdadiene-2,15,16,18-tetrol
N-{1-[4-(2-methoxyphenyl)piperazin-1-yl]propan-2-yl}-N-(pyridin-2-yl)cyclohexanecarboxamide
13-hydroxy-7-oxolabda-8,14-diene 13(R)-O-alpha-L-arabinopyranoside
6alpha,7beta-diacetoxy-13,14-dihydrokolavenic acid methyl ester
9,10-epoxy-6alpha-O-tigloyl-7alphaH-8beta-O-(3-hydroxy-2-methylbutyryl)germacra-3(4)E-ene|trijugin H
2,3-Dihydroxy-24,29-dinor-1,3,5(10),7-friedelatetraene-6,21-dione|6-oxotingenol
2beta,3alpha-Dihydroxy-ent-labd-7-en-15-oic acid methyl ester diacetate
3beta,8alpha,13,14-erythro-tetrahydroxy-labda-15,17-dien-16,19-olide
16-(2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl)-17-nor-coryn-19-ene|4,17-dihydro 17 alpha-tchibangensine
7beta-(1S,5-dimethyl-4-hexenyl)-3aalpha,4,4aalpha,5,6,7,8,8a,9,9aalpha-decahydro-5,8abeta-dimethyl-5-methylenspiro(bicyclo[2.2.2]oct-5-en-2,3(2H)-naphtho[2,3-b]furan)-2-on|7beta-(1S,5-dimethyl-4-hexenyl)-3aalpha,4,4aalpha,5,6,7,8,8a,9,9aalpha-decahydro-5,8abeta-dimethyl-5-methylenspirooct-5-en-2,3(2H)-naphtho<2,3-b>furan>-2-on
(22R)-4beta-hydroxy-1-oxo-witha-2,5,16,24-tetraenolide|(4S,20S,22R)-4-hydroxy-1-oxo-witha-2,5,16,24-tetraenolide
(2alpha,3alpha,7alpha,12?鈥?13?鈥?-3-(2-Methylbutanoyl):2,3,7-Trihydroxy-8(17)-labden-15,12-olide|2alpha,7alpha-dihydroxy-3alpha(2-methylbutanoyloxy)8(17)-labden-12,15-olide
19-(p-hydroxyhydrocinnamoyloxy)-ent-kaurenic acid|19--ent-kaurenic acid
9,13-epoxy-3,18;15,16-bis-isopropylidenedioxy-labdane
12beta-O-acetyl-15alpha,28-dihydoxy-17beta-methoxy-3-oxo-20,21,22,23,24,25,26,27-octanordammanran
6alpha,8alpha,15(S),23-tetrahydroxy-labd-13(14),17-dien-16(S),19-olide
4-hydroxy-2,3-dimethoxy-5-(11-methoxy-3,7,11-trimethyldodeca-2,6-dienyl)-6-methylcyclohex-2-enone
(5S,8R,9S,10R,13S)-2-oxo-13-O-arabinopyranosyl-3,14-clerodadiene
3,3-dimethylundecan-2-yl 4-acetyl-2,3,6-trimethoxybenzoate|asiatoate A
7beta-(1S,5-dimethyl-4-hexenyl)-3aalpha,5,6,7,8,8a,9,9aalpha-octahydro-5,5beta,8abeta-trimethylspiro(bicyclo[2.2.2]oct-5-en-2,3(2H)-naphtho[2,3-b]furan)-2-on|7beta-(1S,5-dimethyl-4-hexenyl)-3aalpha,5,6,7,8,8a,9,9aalpha-octahydro-5,5beta,8abeta-trimethylspirooct-5-en-2,3(2H)-naphtho<2,3-b>furan>-2-on
3,9-dihydroxy-4,6a,6b,8a,11,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione
(20S,22S,23R,24S)-14beta,22:22,25-diepoxy-23-hydroxyergosta-4,6,8,11-tetraen-3-one|blazeispirol U
(3aS,5R,5aS,6aS,7aS,8R,8aS,8bR)-dodecahydro-3a,8b-dihydroxy-5,7a-dimethyl-1-methylideneoxireno[6,7]naphtho[2,1-b]furan-8-yl decanoate|strobilol I
6alpha-hydroxy-17-(alpha-methylbutyroxy)grindelic acid
(13Z,15E,17E,22E)-3beta-hydroxymalabarica-13,15,17,22,24-pentaen-12-one
16-(2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl)-16-nor-coryn-3(14)-ene|3-Dehydrochrolifuanin|3-Dehydroochrolifuanin
Simvastatin acid
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor
(5Z,7E)-(1S,3R)-24-methylsulfonyl-9,10-seco-5,7,10(19)-cholatriene-1,3-diol
24,24-difluoro-1α-hydroxyvitamin D3 / 24,24-difluoro-1α-hydroxycholecalciferol
C27H42F2O2 (436.31526959999997)
4,4-difluoro-1α-hydroxyvitamin D3 / 4,4-difluoro-1α-hydroxycholecalciferol
C27H42F2O2 (436.31526959999997)
(5Z,7E)-(1S,3S)-4,4-difluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
C27H42F2O2 (436.31526959999997)
23,23-difluoro-25-hydroxyvitamin D3 / 23,23-difluoro-25-hydroxycholecalciferol
C27H42F2O2 (436.31526959999997)
24,24-difluoro-25-hydroxyvitamin D3 / 24,24-difluoro-25-hydroxycholecalciferol
C27H42F2O2 (436.31526959999997)
Manglupenone
(R)-1-O-[b-D-Apiofuranosyl-(1->2)-b-D-glucopyranoside]-1,3-octanediol
1alpha-hydroxy-24-methylsulfonyl-25,26,27-trinorvitamin D3
24,24-difluoro-1alpha-hydroxyvitamin D3
C27H42O2F2 (436.31526959999997)
4,4-difluoro-1alpha-hydroxyvitamin D3
C27H42O2F2 (436.31526959999997)
23,23-difluoro-25-hydroxyvitamin D3
C27H42O2F2 (436.31526959999997)
24,24-difluoro-25-hydroxyvitamin D3
C27H42O2F2 (436.31526959999997)
N-[2-[4-(2-METHOXYPHENYL)PIPERAZINO]-1-METHYLETHYL]-N-PYRIDIN-2-YLCYCLOHEXANECARBOXAMIDE
bialamicol
C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent
Bolmantalate
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone
Lifarizine
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker C93038 - Cation Channel Blocker
2-Dicyclohexylphosphino-2,6-bis(N,N-dimethylamino)biphenyl
C28H41N2P (436.30071960000004)
FGIN-1-27
C28H37FN2O (436.28897639999997)
D006133 - Growth Substances > D010937 - Plant Growth Regulators > D007210 - Indoleacetic Acids
(trans,trans)-4-Pentyl-[1,1-bicyclohexyl]-4-carboxylic acid 4-ethoxy-2,3-difluorophenyl ester
dodecyl 2-methylprop-2-enoate,3,3,3-trifluoropropyl 2-methylprop-2-enoate
Cipemastat
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D061965 - Matrix Metalloproteinase Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C1970 - Matrix Metalloproteinase Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor
23,23-difluoro-25-hydroxyvitamin D3
C27H42F2O2 (436.31526959999997)
D018977 - Micronutrients > D014815 - Vitamins > D006887 - Hydroxycholecalciferols
Ergosta-5,7,22,24(28)-tetraen-3beta-yl acetate
A sterol ester that is ergosta-5,7,22,24(28)-tetraen-3beta-ol in which the hydroxyl hydrogen is substituted by an acetyl group.
(1R,3Z)-3-[(2E)-2-[(3aS,7aR)-1-[(2R)-5,5-difluoro-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
C27H42F2O2 (436.31526959999997)
D018977 - Micronutrients > D014815 - Vitamins > D006887 - Hydroxycholecalciferols
pangamic acid
(3Z)-3-[(2E)-2-[1-(5,5-difluoro-6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
C27H42F2O2 (436.31526959999997)
D018977 - Micronutrients > D014815 - Vitamins > D006887 - Hydroxycholecalciferols
Aculeatol E
An oxaspiro compound that is 1,7-dioxadispiro[5.1.5.2]pentadec-9-en-11-one substituted by hydroxy groups at positions 4 and 13 and a tridecyl group at position 2 (the (2R,4R,6S,8R,13S stereoisomer). It is isolated from the leaves of Amomum aculeatum and exhibits toxicity against some cancer cell lines like human lung carcinoma, hormone-dependent lung carcinoma and human breast carcinoma.
(10S,11S)-10-[[cyclopropylmethyl(methyl)amino]methyl]-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
(10S,11R)-10-[[cyclopropylmethyl(methyl)amino]methyl]-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
(10S,11S)-10-[[cyclopropylmethyl(methyl)amino]methyl]-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
(10R,11S)-10-[[cyclopropylmethyl(methyl)amino]methyl]-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
(10R,11S)-10-[[cyclopropylmethyl(methyl)amino]methyl]-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
(10R,11R)-10-[[cyclopropylmethyl(methyl)amino]methyl]-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
2-[(E)-5-[(1R,2R,4S,5S,6R,8aS)-2,4,6-trihydroxy-5-(hydroxymethyl)-2,5,8a-trimethyl-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]-3-methylpent-2-enyl]-3-methyl-2H-uran-5-one
[(E)-2-(hexanoylamino)-3-hydroxynon-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C20H41N2O6P (436.27020960000004)
[(E)-2-acetamido-3-hydroxytridec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C20H41N2O6P (436.27020960000004)
[(E)-3-hydroxy-2-(pentanoylamino)dec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C20H41N2O6P (436.27020960000004)
[(E)-3-hydroxy-2-(propanoylamino)dodec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C20H41N2O6P (436.27020960000004)
[(E)-2-(butanoylamino)-3-hydroxyundec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C20H41N2O6P (436.27020960000004)
[(E)-2-(heptanoylamino)-3-hydroxyoct-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C20H41N2O6P (436.27020960000004)
(6Z,9Z,12Z,15Z,18Z,21Z,24Z,27Z)-triaconta-6,9,12,15,18,21,24,27-octaenoic acid
Labda-7,14-dien-13(R)-OL-alpha-L-6-deoxyidopyranoside
(1-hydroxy-3-pentanoyloxypropan-2-yl) (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
(1-heptanoyloxy-3-hydroxypropan-2-yl) (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
(1-hydroxy-3-propanoyloxypropan-2-yl) (11Z,14Z,17Z)-icosa-11,14,17-trienoate
6-[2,2-Bis[di(propan-2-yl)amino]acetyl]oxy-2,3,4,5-tetrahydroxyhexanoic acid
Paraminabeolide A
A withanolide that is 22,26-epoxyergosta-1,4,24-triene-18-al substituted by oxo groups at positions 3 and 26. Isolated from a Formosan soft coral, Paraminabea acronocephala, it exhibits cytotoxic activity.
(5Z,7E)-(3S)-23,23-difluoro-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol
C27H42F2O2 (436.31526959999997)
(5E,7E)-(1S,3S)-4,4-difluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3-diol
C27H42F2O2 (436.31526959999997)
TG(22:3)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
(1s,3br,4r,5ar,9ar,9br,11as)-1-(furan-3-yl)-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-4-yl acetate
(2r,3s,4r,5r)-6-{[2,2-bis(diisopropylamino)acetyl]oxy}-2,3,4,5-tetrahydroxyhexanoic acid
4-{11-hydroxy-7,7-dimethoxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl}pentanoic acid
2-[(1as,2r,2as,3r,5's,6ar,7s,7as)-3,7-dihydroxy-1a,2a,5',6,6-pentamethyl-hexahydrospiro[naphtho[2,3-b]oxirene-2,2'-oxolan]-5'-yl]ethyl 3-methylbut-2-enoate
2,3-dimethoxy-5-methyl-6-[(2e,6z,9e)-3,7,9-trimethyl-11-phenylundeca-2,6,9-trien-1-yl]pyran-4-one
ethyl (3r,5r)-7-[(1s,2s,8s,8ar)-2-methyl-8-{[(2s)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoate
(1'r,2s,3r,4s,10's,14'r,15'r,16's)-3-hydroxy-4,5,5,10',14',16'-hexamethyl-18'-oxaspiro[oxolane-2,17'-pentacyclo[13.3.2.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]icosane]-2'(11'),3',5',12'-tetraen-7'-one
1-[1-(4,5-dihydroxy-3-methylidenepentyl)-1,4a,5-trimethyl-2,3,4,7,8,8a-hexahydronaphthalen-2-yl]methyl 4-methyl butanedioate
3a,6,6,9b,11a-pentamethyl-1-(6-methylhepta-4,6-dien-2-yl)-1h,2h,3h,3bh,8h,9h,9ah,10h,11h-cyclopenta[a]phenanthrene-4,7-dione
(1r,3as,3br,9as,9bs,11ar)-3a,6,6,9b,11a-pentamethyl-1-[(2r,4e)-6-methylhepta-4,6-dien-2-yl]-1h,2h,3h,3bh,8h,9h,9ah,10h,11h-cyclopenta[a]phenanthrene-4,7-dione
{5-[(acetyloxy)methyl]-1-[2-(5-methoxyoxolan-3-yl)ethyl]-1,2-dimethyl-2,3,4,7,8,8a-hexahydronaphthalen-4a-yl}methyl acetate
3-(6,10-dimethylundeca-3,5,7,9-tetraen-2-ylidene)-7-hydroxy-3a,6,6,9a-tetramethyl-octahydrocyclopenta[a]naphthalen-2-one
methyl 2-{6-methoxy-6-[(14e,16e)-octadeca-14,16-dien-1-yl]-3h-1,2-dioxin-3-yl}acetate
6-{3a,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,3h,4h,5h,5ah,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl}-2-methylhepta-2,4-dienal
(3s,4e,15z,26e,28s)-triaconta-4,15,26-trien-1,12,29-triyne-3,28-diol
5,8'a-dimethyl-7-(6-methylhept-5-en-2-yl)-5'-methylidene-3'a,4',4'a,6',7',8',9',9'a-octahydrospiro[bicyclo[2.2.2]octane-2,3'-naphtho[2,3-b]fura]-5-en-2'-one
9,11,11-trimethyl-2-methylidene-4-({9,11,11-trimethyl-3-oxotricyclo[4.3.2.0¹,⁵]undecan-2-yl}methyl)tricyclo[4.3.2.0¹,⁵]undecan-3-one
(1r,5r,8r)-8-[(1r,3as,3bs,9ar,9bs,11as)-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
(2r)-2,8-dimethyl-2-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]chromen-6-yl acetate
(1r,5s,7r)-7-[(1s,3as,3bs,9ar,9bs,11as)-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
(2s,3r,4s,5r,6r)-2-{[(3r)-5-[(1s,4as,8as)-2,5,5,8a-tetramethyl-1,4,4a,6,7,8-hexahydronaphthalen-1-yl]-3-methylpent-1-en-3-yl]oxy}-6-methyloxane-3,4,5-triol
(1r,3bs,4r,5ar,9as,9bs,11as)-1-(furan-3-yl)-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-4-yl acetate
(1r,5r,9s)-5-{[(1r,4e,9s)-11,11-dimethyl-8-methylidenebicyclo[7.2.0]undec-4-en-4-yl]methoxy}-11,11-dimethyl-4,8-dimethylidenebicyclo[7.2.0]undecan-3-one
(3s,4e,15e,18e,28s)-triaconta-4,15,18-trien-1,12,29-triyne-3,28-diol
[(3s,6s)-6-[(2s,5r)-5-[(9z,11z)-hexadeca-9,11-dien-1-yl]oxolan-2-yl]-1,2-dioxan-3-yl]acetic acid
1,16-dihydroxyhexadecan-7-yl 3-(3,4-dihydroxyphenyl)prop-2-enoate
(1r,2s,5s,6r,10r,11s,12r,15r,19s)-11-ethoxy-6-(furan-3-yl)-1,5,10,15-tetramethyl-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadeca-8,16-dien-18-one
(2r,3r,4s,5r)-3,5-dihydroxy-2-[(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)oxy]oxan-4-yl 2-methylbut-2-enoate
(6bs,7s,8as,11r,12ar,12bs,14as)-3,7-dihydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione
ethyl 3,5-dihydroxy-7-{2-methyl-8-[(2-methylbutanoyl)oxy]-1,2,6,7,8,8a-hexahydronaphthalen-1-yl}heptanoate
1-[(1r,2r,4ar,8ar)-1-[(4s)-4,5-dihydroxy-3-methylidenepentyl]-1,4a,5-trimethyl-2,3,4,7,8,8a-hexahydronaphthalen-2-yl]methyl 4-methyl butanedioate
5-[4-hydroxy-5-(hydroxymethyl)-2,5,8a-trimethyl-6-[(3-methylbutanoyl)oxy]-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]-3-methylpent-2-enoic acid
(8ar,9s,10r,11s,12as,12bs,14as)-3,9,10-trihydroxy-4,7,8a,11,12b,14a-hexamethyl-8,9,10,11,12,12a,13,14-octahydropicen-2-one
methyl (3r)-5-[(1r,2s,3r,4r,4ar,8ar)-3,4-bis(acetyloxy)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]-3-methylpentanoate
6-oxotingenol
{"Ingredient_id": "HBIN012741","Ingredient_name": "6-oxotingenol","Alias": "NA","Ingredient_formula": "C28H36O4","Ingredient_Smile": "CC1CC2C(CCC3(C2(CCC4(C3=CC(=O)C5=C(C(=C(C=C54)O)O)C)C)C)C)(CC1=O)C","Ingredient_weight": "436.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "16418","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "10410773","DrugBank_id": "NA"}
1-{5-[7-hydroxy-5-(hydroxymethyl)-2,5,8a-trimethyl-1,4,4a,6,7,8-hexahydronaphthalen-1-yl]-3-methylpent-2-en-1-yl} 4-methyl butanedioate
(1'r,2s,3r,4s,10's,14's,15'r,16's)-3-hydroxy-4,5,5,10',14',16'-hexamethyl-18'-oxaspiro[oxolane-2,17'-pentacyclo[13.3.2.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]icosane]-2'(11'),3',5',12'-tetraen-7'-one
(1r,3as,5ar,5br,7ar,11ar,11br,13as,13br)-5a,5b,8,8,11a-pentamethyl-9-oxo-1-(prop-1-en-2-yl)-1h,2h,3h,4h,5h,6h,7h,7ah,11bh,12h,13h,13ah,13bh-cyclopenta[a]chrysene-3a-carbaldehyde
1-(5,6-dimethylhept-3-en-2-yl)-5,11a-dimethyl-1h,2h,3h,3ah,6h,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl acetate
methyl 5-[3,4-bis(acetyloxy)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]-3-methylpentanoate
(2e)-n-[(3s,7r,10r)-2,9-dihydroxy-3-isopropyl-7-methyl-5,6-dioxo-1,4,8-triazacyclotrideca-1,8-dien-10-yl]-6-methylhept-2-enimidic acid
2-{[5-(2,5,5,8a-tetramethyl-1,4,4a,6,7,8-hexahydronaphthalen-1-yl)-3-methylpent-1-en-3-yl]oxy}-6-methyloxane-3,4,5-triol
(1r,5s,8r)-8-[(1r,3as,3bs,9ar,9bs,11as)-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
(1r,3r,3as,3br,5s,5as,6r,7s,9ar,9bs,11ar)-1-[(2r,3e,5r)-6-hydroxy-5-methylhex-3-en-2-yl]-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthrene-3,5,6,7-tetrol
(2s,3e,12bs)-3-ethylidene-2-[(1s)-1h,2h,3h,4h,9h-pyrido[3,4-b]indol-1-ylmethyl]-1h,2h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizine
4-hydroxy-5,5,5',8a-tetramethyl-2-{[(2-methylbutanoyl)oxy]methyl}-4a,6,7,8-tetrahydro-4h-spiro[naphthalene-1,2'-oxolan]-5'-ylacetic acid
methyl (1r,2r,4ar,5s,8ar)-2-(acetyloxy)-5-[(3s)-5-(acetyloxy)-3-methylpentyl]-1,4a-dimethyl-6-methylidene-hexahydro-2h-naphthalene-1-carboxylate
(2e,4e,6r)-6-[(1r,3ar,5ar,9as,11ar)-3a,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,3h,4h,5h,5ah,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methylhepta-2,4-dienal
5,5',8'a-trimethyl-7-(6-methylhept-5-en-2-yl)-5',6',7',8',9',9'a-hexahydro-3'ah-spiro[bicyclo[2.2.2]octane-2,3'-naphtho[2,3-b]fura]-5-en-2'-one
(1r,3r,3as,3br,5s,5as,6r,7s,9ar,9bs,11ar)-1-[(2s,3e,5r)-6-hydroxy-5-methylhex-3-en-2-yl]-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthrene-3,5,6,7-tetrol
3-ethylidene-2-{1h,2h,3h,4h,9h-pyrido[3,4-b]indol-1-ylmethyl}-1h,2h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizine
(6bs,8as,11r,12ar,12bs,14ar)-3-hydroxy-11-(hydroxymethyl)-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,10,12,12a,13,14-octahydropicen-2-one
3-ethenyl-2-{1h,2h,3h,4h,9h-pyrido[3,4-b]indol-1-ylmethyl}-1h,2h,3h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizine
(2s,3r,4s,5s,6s)-2-{[(3r)-5-[(1s,4as,8as)-2,5,5,8a-tetramethyl-1,4,4a,6,7,8-hexahydronaphthalen-1-yl]-3-methylpent-1-en-3-yl]oxy}-6-methyloxane-3,4,5-triol
7-{9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
1-[(1s,2r,4as,8ar)-1-[(3r)-4-methoxy-3-methyl-4-oxobutyl]-1,2,5-trimethyl-2,3,4,7,8,8a-hexahydronaphthalen-4a-yl]methyl 4-methyl butanedioate
1-(6-hydroxy-5-methylhex-3-en-2-yl)-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthrene-3,5,6,7-tetrol
(6bs,8ar,9s,11r,12as,12bs,14ar)-3,9-dihydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione
(2r)-2-[(3s,3as,5as,7s,8r,10ar,10br)-8-[(2s)-1,2-dihydroxypropan-2-yl]-3a,10b-dimethyl-5'-oxo-decahydro-1h-spiro[cyclohepta[e]indene-7,2'-oxolan]-3-yl]propanoic acid
(2r,3r,4s,5r)-3,5-dihydroxy-2-{[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]oxy}oxan-4-yl (2z)-2-methylbut-2-enoate
(1'r,2s,3r,4s,14's,15'r,16's)-3-hydroxy-4,5,5,10',14',16'-hexamethyl-18'-oxaspiro[oxolane-2,17'-pentacyclo[13.3.2.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]icosane]-2'(11'),3',5',12'-tetraen-7'-one
1-[1-(4-methoxy-3-methyl-4-oxobutyl)-1,2,5-trimethyl-2,3,4,7,8,8a-hexahydronaphthalen-4a-yl]methyl 4-methyl butanedioate
(4r)-4-[(9as,11s,11ar)-11-hydroxy-7,7-dimethoxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]pentanoic acid
11-hydroxy-10-methoxy-2,4a,6a,9,12b,14a-hexamethyl-2,4,5,6,6b,13,14,14b-octahydro-1h-picen-3-one
(6ar,6br,8as,11r,12ar,12bs,14ar)-3-hydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydro-6ah-picene-2,6,10-trione
(5s)-5-[(2e)-5-[(1r,2r,4s,4ar,5r,6s,8as)-2,4,6-trihydroxy-5-(hydroxymethyl)-2,5,8a-trimethyl-hexahydro-1h-naphthalen-1-yl]-3-methylpent-2-en-1-yl]-4-methyl-5h-furan-2-one
methyl (1r,4s,5r,9s,10s,13r,15s)-15-(benzoyloxy)-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate
methyl 2-(acetyloxy)-5-[5-(acetyloxy)-3-methylpentyl]-1,4a-dimethyl-6-methylidene-hexahydro-2h-naphthalene-1-carboxylate
(1s,5r,6s,9s)-9,11,11-trimethyl-2-methylidene-4-{[(1s,5s,6s,9s)-9,11,11-trimethyl-3-oxotricyclo[4.3.2.0¹,⁵]undecan-2-yl]methyl}tricyclo[4.3.2.0¹,⁵]undecan-3-one
2,8-dimethyl-2-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]chromen-6-yl acetate
(1s,4r,5s,6s,9s)-9,11,11-trimethyl-2-methylidene-4-{[(1s,2s,5s,6s,9s)-9,11,11-trimethyl-3-oxotricyclo[4.3.2.0¹,⁵]undecan-2-yl]methyl}tricyclo[4.3.2.0¹,⁵]undecan-3-one
(1r,5r,9s)-5-{[(1r,4z,9s)-11,11-dimethyl-8-methylidenebicyclo[7.2.0]undec-4-en-4-yl]methoxy}-11,11-dimethyl-4,8-dimethylidenebicyclo[7.2.0]undecan-3-one
2-[8-(1,2-dihydroxypropan-2-yl)-3a,10b-dimethyl-5'-oxo-decahydro-1h-spiro[cyclohepta[e]indene-7,2'-oxolan]-3-yl]propanoic acid
(2s,3r,12bs)-3-ethenyl-2-[(1r)-1h,2h,3h,4h,9h-pyrido[3,4-b]indol-1-ylmethyl]-1h,2h,3h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizine
(6as,6br,8as,11r,12ar,12bs,14ar)-3-hydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydro-6ah-picene-2,6,10-trione
(2s,3r,4r,5r,6s)-2-{[(3r)-5-[(1s,4as,8as)-2,5,5,8a-tetramethyl-1,4,4a,6,7,8-hexahydronaphthalen-1-yl]-3-methylpent-1-en-3-yl]oxy}-6-methyloxane-3,4,5-triol
(3ar,7r,7as)-6-[(3ar,9r,9as)-9-hydroxy-2,2,9-trimethyl-4-oxo-1h,3h,3ah,9ah-cyclopenta[b]naphthalen-6-yl]-7-hydroxy-2,2,7-trimethyl-1,3,3a,7a-tetrahydroinden-4-one
7-{5-[(1s,2r,4ar,8ar)-1,2,4a,5-tetramethyl-7-oxo-3,4,8,8a-tetrahydro-2h-naphthalen-1-yl]-3-methylpent-2-en-1-yl}-6-amino-9-methylpurin-9-ium
[(1s,4s,5r,9s,10r,13r)-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-5-yl]methyl 3-(4-hydroxyphenyl)propanoate
methyl (3r,5r)-7-[(1s,2s,6r,8s,8ar)-2,6-dimethyl-8-{[(2s)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoate
1-{5-[2-(5-methoxyoxolan-3-yl)ethyl]-5,6,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl}methyl 3-methyl propanedioate
(2s,3s,4r,5r)-2-{[(3e)-4-[(2r,3r)-3-[(3r,4r)-4-ethenyl-4-methyl-3-(prop-1-en-2-yl)cyclohexyl]-3-methyloxiran-2-yl]-2-methylbut-3-en-2-yl]oxy}oxane-3,4,5-triol
(7r)-1,16-dihydroxyhexadecan-7-yl (2e)-3-(3,4-dihydroxyphenyl)prop-2-enoate
(2s,3r)-2-[(2s,4r,6e)-4,6-dimethyloct-6-en-2-yl]-6-oxooxan-3-yl (2e,4e,6r)-8-hydroxy-6-(hydroxymethyl)-4-methylocta-2,4-dienoate
methyl 15-(benzoyloxy)-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate
2-oxatricyclo[22.2.2.1³,⁷]nonacosa-1(26),3,5,7(29),13,16,24,27-octaene-5,26,27-triol
3,7-dihydroxy-1,1,4a-trimethyl-5-[(3-methyl-5-oxooxolan-2-yl)methyl]-6-methylidene-hexahydro-2h-naphthalen-2-yl 2-methylbutanoate
(9z,12z)-n-[2-(1h-indol-3-yl)-2-oxoethyl]octadeca-9,12-dienimidic acid
3,9-dihydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione
(1r,2r,10r,11s,14r,15r,16s)-16-[(2r)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]-10,14,16-trimethyl-17-oxapentacyclo[13.2.2.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]nonadeca-4,6-dien-9-one
(6bs,8as,11s,12ar,12bs,14ar)-3,11-dihydroxy-4,6b,8a,11,12b,14a-hexamethyl-8,9,12,12a,13,14-hexahydro-7h-picene-2,10-dione
1-[(4ar,5s,6r,8ar)-5-{2-[(3s,5s)-5-methoxyoxolan-3-yl]ethyl}-5,6,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]methyl 3-methyl propanedioate
(14z,17z)-2-oxatricyclo[22.2.2.1³,⁷]nonacosa-1(26),3,5,7(29),14,17,24,27-octaene-5,26,27-triol
(6bs,8as,11r,12ar,14ar)-3,11-dihydroxy-4,6b,8a,11,12b,14a-hexamethyl-8,9,12,12a,13,14-hexahydro-7h-picene-2,10-dione
(4e,15z,26e)-triaconta-4,15,26-trien-1,12,29-triyne-3,28-diol
(4as,8as)-3,4a,8,8-tetramethyl-4-[(3r)-3-methyl-3-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}pent-4-en-1-yl]-5,6,7,8a-tetrahydro-1h-naphthalen-2-one
10,11-dihydroxy-2,4a,6a,9,12b,14a-hexamethyl-1,2,4,5,6,13,14,14b-octahydropicene-3,8-dione
(2s,3r,4as,5r,7r,8ar)-3,7-dihydroxy-1,1,4a-trimethyl-5-{[(2s,3r)-3-methyl-5-oxooxolan-2-yl]methyl}-6-methylidene-hexahydro-2h-naphthalen-2-yl (2r)-2-methylbutanoate
methyl 2-[(3r,6r)-6-methoxy-6-[(14e,16e)-octadeca-14,16-dien-1-yl]-3h-1,2-dioxin-3-yl]acetate
2,6-dihydroxy-8,13-dimethyl-3-methylidene-5,12-dioxatetracyclo[7.5.0.0²,⁶.0¹¹,¹³]tetradecan-14-yl decanoate
2,8-dimethyl-2-(4,8,12-trimethyltrideca-3,7,11-trien-1-yl)chromen-6-yl acetate
3,7-dihydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione
3,4a,8,8-tetramethyl-4-{3-methyl-3-[(3,4,5-trihydroxyoxan-2-yl)oxy]pent-4-en-1-yl}-5,6,7,8a-tetrahydro-1h-naphthalen-2-one
n-[2-(1h-indol-3-yl)-2-oxoethyl]octadeca-9,12-dienimidic acid
6-amino-7-[(2e)-3,7-dimethyl-9-[(1r,6s)-1,2,6-trimethyl-4-oxocyclohex-2-en-1-yl]nona-2,6-dien-1-yl]-9-methylpurin-9-ium
(1r,2s,3'ar,4r,5's,7s,8'ar,9'ar)-5,5',8'a-trimethyl-7-[(2s)-6-methylhept-5-en-2-yl]-5',6',7',8',9',9'a-hexahydro-3'ah-spiro[bicyclo[2.2.2]octane-2,3'-naphtho[2,3-b]fura]-5-en-2'-one
(1s,4s,4as,5'r,8as)-4-hydroxy-5,5,5',8a-tetramethyl-2-({[(2r)-2-methylbutanoyl]oxy}methyl)-4a,6,7,8-tetrahydro-4h-spiro[naphthalene-1,2'-oxolan]-5'-ylacetic acid
(1s,2r,6s,8r,9s,11s,13s,14r)-2,6-dihydroxy-8,13-dimethyl-3-methylidene-5,12-dioxatetracyclo[7.5.0.0²,⁶.0¹¹,¹³]tetradecan-14-yl decanoate
4,13-dihydroxy-2-tridecyl-1,7-dioxadispiro[5.1.5⁸.2⁶]pentadec-9-en-11-one
ethyl 4-{4,7,11-trihydroxy-9a,11a-dimethyl-tetradecahydro-1h-cyclopenta[a]phenanthren-1-yl}pentanoate
1-[(4ar,5s,6r,8ar)-5-{2-[(3s,5r)-5-methoxyoxolan-3-yl]ethyl}-5,6,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]methyl 3-methyl propanedioate
(3r)-n-{2-[(1e,7ar)-3-oxo-tetrahydropyrrolo[1,2-c][1,3]oxazol-1-ylidene]acetyl}-3-hydroxyhexadecanimidic acid
C24H40N2O5 (436.29370700000004)